{"nctId":"NCT02536508","briefTitle":"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","startDateStruct":{"date":"2015-08-10","type":"ACTUAL"},"conditions":["COPD"],"count":627,"armGroups":[{"label":"BGF MDI (PT010) 320/14.4/9.6 μg","type":"EXPERIMENTAL","interventionNames":["Drug: BGF MDI 320/14.4/9.6 μg"]},{"label":"GFF MDI (PT003) 14.4/9.6 μg","type":"EXPERIMENTAL","interventionNames":["Drug: GFF MDI 14.4/9.6 μg"]},{"label":"BFF MDI (PT009) 320/9.6 μg","type":"EXPERIMENTAL","interventionNames":["Drug: BFF MDI 320/9.6 μg"]}],"interventions":[{"name":"BGF MDI 320/14.4/9.6 μg","otherNames":["BGF MDI"]},{"name":"GFF MDI 14.4/9.6 μg","otherNames":["GFF MDI"]},{"name":"BFF MDI 320/9.6 μg","otherNames":["BFF MDI"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nGiven their signed written informed consent to participate. Must have agreed to participate in and complete the lead-in Study PT010006.(NCT02497001)\n\nExclusion Criteria:\n\nSevere osteoporosis Unable to achieve an acceptable DEXA scan Inability to achieve pupil dilation to at least 6 mm Subjects with an implanted artificial intraocular lens or are scheduled to undergo cataract surgery","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in BMD of the Lumbar Spine","description":"Percent change from baseline in BMD of the lumbar spine T-Score at Week 52.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.093","spread":null},{"groupId":"OG001","value":"0.379","spread":null},{"groupId":"OG002","value":"-0.120","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in the LOCS III (P) Score at Week 52","description":"Change from baseline in the LOCS III (P) score (Severity of Posterior Subcapsular Cataract) at Week 52. P score is reported as a decimalized scale ranging from 0.1 (indicating a completely clear or colorless lens) to 5.9 (indicating complete opacification on the posterior capsule). A negative change in P score indicates an improvement and a positive change indicates a deterioration of LOCS III. A change in P score within 0.5 is an acceptable variation margin.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.153","spread":null},{"groupId":"OG001","value":".026","spread":null},{"groupId":"OG002","value":"0.022","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":194},"commonTop":["Upper Respiratory Tract Infection","Bronchitis","Viral Upper Respiratory Tract Infection","Urinary Tract Infection","Sinusitis"]}}}